JAK1 and acute lymphoblastic leukemia: AZD1480 was tested against a total of 52 PDX models (41 solid tumor and 11 ALL, including 7 harboring JAK1/2 mutations) (Houghton et al., 2014; Suryani et al., 2015), while ruxolitinib was tested against 8 ALL models, both agents being administered on protracted dosing schedules.